




CYTOMOS.

SEE THE UNSEEN



Company Overview

Cytomos is a cutting-edge techbio company and University of Edinburgh spin-out, pioneering a paradigm shift in cell analytics by using the physics of the cell to predict biology. The company's proprietary platform, Celledonia[®] powered by AuraCyt[®], delivers predictive cell analytics by capturing a digital fingerprint of every cell, generating rapid, high-resolution insights into cell health, phenotype, and function.

Celledonia is a benchtop, label-free cell analysis platform that enables researchers and therapy developers to understand and predict cell behaviour at the press of a button. By revealing intrinsic cellular properties, including features for which no biomarkers exist, the platform provides actionable, data-driven insights to support faster, more reliable decision-making across research, development, and manufacturing.

Cytomos' mission is to redefine how living cells are understood and controlled, accelerating discovery, development, and scale-up across advanced therapies, cell line development, immunotherapies, differentiation-capable cells, and biologics.

Key Challenges Addressed

Traditional cell analysis methods are often slow, complex, and reliant on labels or biomarkers, limiting the ability to fully understand cell state and predict behaviour. This creates significant challenges in biomanufacturing, including inefficient process optimisation, variability in product quality, and limited ability to anticipate failure.

Cytomos addresses these challenges through predictive, label-free cell analytics. By providing early insight into how cells will behave during processing, Celledonia enables faster process optimisation, improved product consistency, and a deeper understanding of the drivers of cellular performance.

Beyond the technology itself, Cytomos works closely with customers to ensure successful implementation and impact. Its team of scientists and data analysts collaborate directly with partners, both on-site and remotely, to integrate the platform into existing workflows and maximise value.



Role of Roslin Innovation Centre

Since establishing at the Roslin Innovation Centre, Cytomos has gained access to specialised equipment and scientific networks on the University of Edinburgh Easter Bush Campus. As the company has grown, it has expanded into a larger facility at Edinburgh Technopole, a science park adjacent to the campus, while remaining an active Member of Roslin Innovation Centre. This strategic expansion enables Cytomos to maintain close ties to the local innovation ecosystem, benefiting from a strong cluster of life science companies, access to research resources, and opportunities for collaboration, knowledge exchange, and talent development.

Collaborations fostered through Roslin Innovation Centre have helped Cytomos build partnerships with major biotechnology and pharmaceutical companies, as well as bioreactor platform providers and therapy developers. These relationships have yielded proof-of-concept studies, collaboration projects, and planned trials in North America, EU and UK, supported by Scottish Enterprise and Innovate UK.

With continued support from Roslin Innovation Centre's network, Cytomos has advanced its innovative, label-free, rapid cellular analysis platform, which is poised to transform the biologics industry and cell and gene therapy manufacturing. The technology is designed to reduce development timelines and costs while enhancing process predictability and scalability, supporting more sustainable biomanufacturing.